Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain
| Autor: | Banz, Kurt, Bischoff, Helge, Brunner, Matthias, Chouaid, Christos, de Castro Carpeño, Javier, de Marinis, Filippo, Grossi, Francesco, Vergnenègre, Alain, Walzer, Stefan |
|---|---|
| Zdroj: | In Lung Cancer December 2011 74(3):529-534 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect